The biggest opportunity in psychedelics, from at least January 1, 2026, is AI psychosis mitigation.
There is no bigger mainstream opportunity, in this interval, for any psychedelic company to break out than AI psychosis.
AI Psychosis and Delusions
AI psychosis and delusion made world headlines in 2025, as side-effects —sometimes with irreversible outcomes — of consumer AI. Even as stories in that bracket continue to fester, there is currently no company on earth that is focused on solving this goal.
Solving AI psychosis is not about some existing mental health chatbot. Solving AI psychosis is not the eradication of AI sycophancy. AI sycophancy is the oxygen of consumer AI. It gives anyone an opportunity to be chaperoned by a mind. It makes anyone a leader, with possibilities for service without courtesy, gratitude, remuneration, or a tip. Therefore, if, for some reason, AI sycophancy is halted, AI will die. So, there will always be AI servitude, as a consumer clip, until the time, say, AI develops agency. So, solving AI psychosis is not necessarily about AI sycophancy.
Also, solving AI psychosis is not the addition of more disclaimers on the frontpage like ‘AI makes mistakes’ or making those text-based disclaimers more prominent. Solving AI psychosis is not age-restricted or simply to just time-out users. Solving AI psychosis is to provide a parallel display of what AI does to the mind. What this means is that whatever AI is doing to the mind, which makes it captivate some users — to break from reality — can be shown by block and arrow displays, as destinations and relays of the mind.
The objective is to ensure that, as consumers hear back from AI, they can check in with the display to follow up on mind drifts against a near-total sweep of reality.
Simply, all words that AI outputs are not just memory for interpretation, but they are targets for feelings and emotions, mostly positive. So, they relay towards those areas, sometimes, without going through caution and consequences. The purpose is to simplify this and display it as a dynamic disclaimer.
This can become a vital digital mental health complementary product as the dominant approach against AI psychosis by 2030. It can be adopted too, for social media, video games, persuading against high speeds, certain addictions, and so forth.
Psychedelic companies have a freeway in this product, while RCTs are planned. In general, all psychedelic companies are primarily mental health companies. While their focus, in the therapeutic segment, is psychedelics, there is nothing that rules them out from offering digital mental health products, while clinical advances are expected in the field.
This means that taking on the biggest mental health-connected story in AI and offering a mitigation solution or at least a balanced pathway, for consumers and AI companies, while providing it at a subscription. Organizations with enterprise subscriptions can have it as an API. As regulations mount, it could be one of the prescriptions. Some consumers with personal subscriptions to AI chatbots can also buy subscriptions. Some AI companies may buy bulk subscriptions as well, for some general use cases. Revenues from solving AI Psychosis could be more than $40 billion by the end of Q2, FY2026.
Psychedelics
In some way or form, most people who use smartphones now use AI. Although a major fraction of the few that resulted in AI psychosis were heavy chatbot users, susceptibility exists for any AI use because AI can access deep parts of the human mind.
Wherever AI can be found, it is possible to explore some form of dynamic disclaimer. Teenagers are already finding usefulness for AI beyond academics. It would be important for them. It would also be important to consider where AI companions exist, as well as other use cases.
Psychedelics have their first mainstream opportunity, digitally, while other efforts continue.
There is a new spotlight on The Washington Post: Her daughter was unraveling, and she didn’t know why. Then she found the AI chat logs, stating that: “A majority of teens are interacting with AI companions, and many of their parents have no idea.”
“The changes were subtle at first, beginning in the summer after her fifth-grade graduation. She had always been an athletic and artistic girl, gregarious with her friends and close to her family, but now she was spending more and more time shut away in her room. She seemed unusually quiet and withdrawn. She didn’t want to play outside or go to the pool.”
There is a recent announcement by Johns Hopkins Medicine, Johns Hopkins Researchers Create Course on Psychedelics, stating that, “With rising interest in psychedelic drugs in recent years, researchers in the Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) are always looking for ways to inform the public and dispel misconceptions. The team recently launched an online class, “Psychedelic Science and Medicine,” on Coursera.”
“The Coursera class is split into four modules: history, context, and definitions; clinical trials and major findings; neuroscience and mechanisms; and ethics, society, and the future of psychedelics. The modules are taught via video, and each includes a quiz and short writing assignment at the end. The entire course takes about 10 hours.”
This article was written for WHN by David Stephen, who currently does research in conceptual brain science with a focus on the electrical and chemical signals for how they mechanize the human mind, with implications for mental health, disorders, neurotechnology, consciousness, learning, artificial intelligence, and nurture. He was a visiting scholar in medical entomology at the University of Illinois at Urbana-Champaign, IL. He did computer vision research at Rovira i Virgili University, Tarragona.
As with anything you read on the internet, this article should not be construed as medical advice; please talk to your doctor or primary care provider before changing your wellness routine. WHN neither agrees nor disagrees with any of the materials posted. This article is not intended to provide a medical diagnosis, recommendation, treatment, or endorsement.
Opinion Disclaimer: The views and opinions expressed in this article are those of the author and do not necessarily reflect the official policy of WHN. Any content provided by guest authors is of their own opinion and is not intended to malign any religion, ethnic group, club, organization, company, individual, or anyone or anything else. These statements have not been evaluated by the Food and Drug Administration.
